PMPeter Mikosch

Peter Mikosch

*This is an algorithmically generated author record based on publicly available information.

Peter Mikosch has a total of 72 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Changes of Bone Metabolism in Seven Patients with Gaucher Disease Treated Consecutively with Imiglucerase and Miglustat

    by P. Mikosch, M. Reed, R. Baker, B. Holloway, L. Berger, A. B. Mehta, D. A. Hughes

    Bone manifestations are frequent in Gaucher disease (GD), the most prevalent lysosomal storage disorder. Currently, therapy with enzyme replacement (ERT) or substrate reduction (SRT) is available. We investigated changes of laboratory parameters associated with bone metabolism in GD patients switching from ERT to SRT. Seven GD patients consecutively treated with ERT and SRT were studied. All patients had different degrees of bone involvement. Laboratory results were acquired at the time of change from ERT to SRT (0 months) and while on SRT (6 months, 12–18 months). Markers of GD activity remained stable or showed statistically insignificant increases. Six patients had stable skeletal manifestations and reported no bone-associated symptoms. One patient presented progressive bone manifestations on magnetic resonance imaging and experienced increasing bone pain. Osteocalcin, alkaline phosphatase, and C-terminal telopeptide of collagen I were initially within the lower part of the normal range and decreased during SRT (alkaline phosphatase P = 0.0169, osteocalcin nonsignificant, C-terminal telopeptide of collagen I nonsignificant). Tartrate-resistant acid phosphatase 5b was initially normal or slightly increased, and macrophage colony-stimulating factor was within the normal lower range; both parameters remained stable. Interleukin-6 was elevated only in the patient with progressive bone disease. Macrophage inflammatory protein 1α (MIP-1α) was elevated without change after switching to SRT. MIP-1β was within the normal range, and no values were above 85 ng/mL, indicative of active skeletal disease. From a clinical and metabolic point of view, most skeletal manifestations and bone-associated laboratory parameters remain stable after switch from ERT to SRT.


    • 1 January 2008
      • Vol. 47  (6) , 239-47

    Is there a role for scintigraphic imaging of bone manifestations in Gaucher disease? A review of the literature.

    by P Mikosch, S Kohlfürst, H J Gallowitsch, E Kresnik, P Lind, A B Mehta, D A Hughes

    Gaucher disease is the most prevalent inherited, lysosomal storage disease and is caused by deficient activity of the enzyme beta-glucocerebrosidase. Bone and bone marrow alterations are frequent in the most prevalent non-neuronopathic form of Gaucher disease. Imaging of bone manifestations in Gaucher disease is performed by a variety of imaging methods, conventional X-ray and MRI as the most frequently and most important ones. However, different modalities of scintigraphic imaging have also been used. This article gives an overview on scintigraphic imaging with respect to bone manifestations in Gaucher disease discussing the advantages and limitations of scintigraphic imaging in comparison to other imaging methods.


  • Is there a role for scintigraphic imaging of bone manifestations in Gaucher disease?

    by S. Kohlfürst, H. J. Gallowitsch, E. Kresnik, P. Lind, A. B. Mehta, D. A. Hughes, P. Mikosch

    Summary: Gaucher disease is the most prevalent inherited, lysosomal storage disease and is caused by deficient activity of the enzyme β-glucocerebrosidase. Bone and bone marrow alterations are frequent in the most prevalent non-neuronopathic form of Gaucher disease. Imaging of bone manifestations in Gaucher disease is performed by a variety of imaging methods, conventional X-ray and MRI as the most frequently and most important ones. However, different modalities of scintigraphic imaging have also been used. This article gives an overview on scintigraphic imaging with respect to bone manifestations in Gaucher disease discussing the advantages and limitations of scintigraphic imaging in comparison to other imaging methods.


    • 1 January 2007
      • Vol. 46  (6) , 252-6

    Sentinel node SPECT-CT in breast cancer. Can we expect any additional and clinically relevant information?

    by H-J Gallowitsch, P Kraschl, I Igerc, T Hussein, E Kresnik, P Mikosch, S Kohlfuerst, K Hausegger, P Lind

    The AIM of this study was to determine the additional value of SPECT/CT in sentinel node scintigraphy in breast cancer. Furthermore, it was our question to determine, whether the low-dose computed tomography component (LD-CT) can be used for axillary lymph node staging of clinically negative patients. 51 patients with invasive breast cancer <3 cm in diameter were included in our prospective investigation. SPECT/CT was performed on a dedicated scanner 30 minutes after subareolar injection of (99m)Tc-Nanocoll. Axillary staging with CT(LD) was performed using standard CT-criteria. SLN were allocated to an axillary level using SPECT alone and SPECT/CT. Additionally, the number of SLN on CT(LD) corresponding to the scintigraphic hot node was notified for each patient and compared to the number of SLN found with the gamma probe. In 45/51 evaluable patients SLN could be localised in level I in 43 patients and in level II in two patients (all positive) using SPECT-CT, whereas a clear allocation could not be obtained by SPECT alone. The number of SLN was discrepant between SPECT and CT(LD) in 13/45 patients. The number of SLN detected with the gamma probe (n = 68) not significantly differed from the number of SLN detected by CT(LD) (n = 65) but was significantly higher than with SPECT (n = 51). CT(LD) yielded a sensitivity of 35.7%, a specificity of 83.9%, a positive predictive value (PPT) of 50%, a negative predictive value (NPV) of 74.3% and a diagnostic accuracy of 68.9% for axillary staging with CT(LD). The additional information of SPECT/CT allows a more accurate characterization of the SN concerning size, depth and anatomical location. CT(LD) when performed during (99m)Tc-Nanocoll sentinel-SPECT/CT is not suitable for axillary staging in breast cancer patients with clinical negative axilla due to its low sensitivity and moderate specificity. Therefore, it does not influence the decision for SNB or ALND. The limited resolution of SPECT leads to an underestimation of the number of SLN compared to CT(LD) and the gamma probe.


  • Receptor activator of nuclear factor κB ligand and osteoprotegerin in men with thyroid cancer

    by P. Mikosch, I. Igerc, S. Kudlacek, W. Woloszczuk, H. J. Gallowitsch, E. Kresnik, H. Stettner, G. Grimm, P. Lind, P. Pietschmann

    Background  Suppressive thyroid hormone therapy is generally a lifelong treatment for patients with differentiated thyroid cancer (DTC). However, long‐standing thyrotropin (TSH) suppression is a risk factor for osteoporosis. Osteoprotegerin (OPG) and receptor activator of nuclear factor κB ligand (RANKL) are central regulators of bone turnover. The aim was to analyze the effects of a suppressive thyroid hormone therapy in males with DTC on the OPG/RANKL system and on bone metabolism.Patients and methods  The OPG and soluble RANKL (sRANKL) were determined in 40 men (mean age, 53·2 years) with DTC on suppressive thyroid hormone therapy (TSH; 0·053 ± 0·037 mU L−1, duration 5·7 ± 4·4 years) and 120 healthy controls matched for age. The markers of bone metabolism were C‐terminal telopeptide of type I collagen in serum (sCTx) and osteocalcin (OC).Results  The control group had OPG values (mean ± SD) of 1·9 ± 1·0 pmol L−1 and sRANKL values of 0·40 ± 0·62 pmol L−1. In patients with DTC, results for OPG were 3·03 ± 1·04 pmol L−1 (P < 0·05) and for sRANKL were 0·13 ± 0·16 pmol L−1 (P < 0·05). The control group presented values for sCTx of 2669 ± 1132 pmol L−1 and for OC of 17·89 ± 6·5 ng mL−1. Patients with DTC on suppressive thyroid hormone therapy had increased sCTx values of 3810 ± 2020 pmol L−1 (P = 0·03) but comparable OC values of 19·21 ± 7·67 ng mL−1 (NS).Conclusion  Suppressive thyroid hormone therapy in men with DTC increased bone degradation and induced significant changes in the OPG/RANKL system. These changes include, besides the risk of osteoporosis, possible negative effects on the vascular function and an increased risk of cardiovascular disease.


  • Effects of thyroid disorders on the bone

    by Peter Mikosch

    Interactions between thyroid hormones and the bone are complex and are still not fully understood. During development, thyroid hormone is essential for the recruitment and maturation of bone cells. A deficit of thyroid hormone during pregnancy and in the newborn leads to retardation of the skeleton. Hypothyroidism during later life causes a relevant decrease of bone turnover. Excessive amounts of thyroid hormone induce increased activity of osteoblasts and osteoclasts leading to high bone turnover and a loss of BMD, as the activity of osteoclasts predominates over the activity of osteoblasts. In subclinical hyperthyroidism, premenopausal women show no significant BMD loss, whereas postmenopausal women face a significant BMD loss. Men seem to have a limited, but significant bone loss in subclinical hyperthyroidism. Therapeutic consequences focus on the normalization of thyroid function, which can lead to restoration of BMD and normalization of bone turnover. In particular, patients on long-term suppressive L-thyroxine therapy or anti-thyroid drug medication benefit from additional antiresorptive treatment. This article surveys the complex interactions between thyroid hormones and bone cells and their effects on bone turnover, BMD and fractures according to the different states of thyroid function.


  • Editorial

    by P. Mikosch

  • Accuracy of Whole‐Body18F‐FDP‐PET for Restaging Malignant Lymphoma

    by P. Mikosch, H. J. Gallowitsch, W. Zinke‐Cerwenka, M. Heinisch, W. Pipam, M. Eibl, E. Kresnik, O. Unterweger, W. Linkesch, P. Lind

    Summary:Background:The aim of this retrospective study was to evaluate the accuracy of fluorine‐18 fluorodeoxyglucose positron emission tomography (18F‐FDG‐PET) images, which were interpreted under daily routine conditions, in patients with Hodgkin's disease (HD) or non‐Hodgkin lymphoma (NHL) for restaging after chemotherapy and/or radiotherapy. For this purpose,18F‐FDG‐PET results were compared with morphological imaging methods and the patients’ clinical background.Methods:121 PET images of 93 lymphoma patients (44 HD, 49 NHL) were investigated after chemotherapy/radiotherapy. For PET imaging, 160–200 MBq18F‐FDG was administered intravenously, followed by an infusion of 20 mg Furosemid in 250 mL saline. Whole‐body18F‐FDG‐PET images were obtained using a partial‐ring PET scanner without attenuation correction. The morphological imaging consisted in computed tomography and ultrasound (CT/US) in all patients, additional MRI in some patients, and iliac crest biopsy in cases of suspicious bone marrow involvement. The standard of reference was composed of biopsy data, clinical status at the time of investigation, and follow‐up of at least 12 months. The PET images were evaluated for their sensitivity, specificity and accuracy based on written reports, which were compiled from other imaging data and the clinical history of the patients.Results:Sensitivity, specificity, and accuracy of18F‐FDG‐PET was 91 %, 81 %, and 85 %; of CT/US, 88 %, 35 %, 56 %, respectively. Major sources of error in18F‐FDG‐PET were due to asymmetric muscular hypermetabolism and inflammatory lesions misinterpreted as persistent viable lymphoma tissue. Furthermore, secondary malignancies other than lymphomas were another reason for misinterpretations of18F‐FDG‐PET studies.Conclusions:18F‐FDG‐PET showed a comparable sensitivity but a higher specificity and accuracy compared with CT/US. To achieve a high accuracy in18F‐FDG‐PET, the nuclear medicine specialist needs imaging and clinical data as background information, which can only be acquired through close co‐operation with the referring clinicians. Pharmacological muscular relaxation in the course of18F‐FDG‐PET imaging may be advisable, as nonspecific muscular hypermetabolism was one of the problems at the image readings and a source of incorrect18F‐FDG‐PET interpretations.


  • Bone Metabolism in Patients with Differentiated Thyroid Carcinoma Receiving Suppressive Levothyroxine Treatment

    by P. Mikosch, B. Obermayer-Pietsch, R. Jost, B. Jauk, H.J. Gallowitsch, E. Kresnik, G. Leb, P. Lind

    Aim: Patients with differentiated thyroid carcinoma (DTC) must receive suppressive levothyroxine (LT4) therapy for the rest of their lives. The literature, however, presents conflicting results on how this affects bone metabolism. The aim of this study was to assess the influence of the estrogen status and LT4 therapy, in particular LT4 dosage in micrograms per kilograms (μg/kg), on bone metabolism in female patients with DTC. Material and Methods: Three markers of bone metabolism (C-terminal telopeptide of type I collagen in serum [SCTx]; N-terminal telopeptide of type I collagen in urine [U-NTx]; and osteocalcin [OC]) were investigated in four groups: group REF (healthy premenopausal female controls), group DTC-ES (premenopausal women with DTC and normal estrogen levels), group DTC-ED (postmenopausal women with DTC and estrogen deficiency), and group DTC-HRT (postmenopausal women with DTC undergoing hormone replacement therapy [HRT]). All patients with DTC were on a well-adjusted suppressive LT4 therapy with TSH levels 0.1 mU/L or less. Results: In group DTC-ES bone turnover was comparable to group REF, whereas in group DTC-ED, all three markers were significantly increased as compared to groups REF and DTC-ES. In group DTC-HRT, the HRT normalized U-NTx and OC. However, in this group S-CTx was not completely normalized by HRT in all patients, although also significantly lowered compared to group DTC-ED. The analysis of LT4 dosage per kilogram showed that premenopausal DTC-patients had increased markers of bone metabolism if LT4 dosage exceeded 2.6 μg/kg. Estrogen-deficient patients with DTC, however, had a much lower critical LT4 dosage, above which increased markers of bone metabolism were seen. Conclusion: A well-adjusted suppressive LT4 therapy of less than 2.6 μg/kg and normal estrogen levels do not seem to increase bone metabolism in estrogen-sufficient patients with DTC. The normalization of an estrogen deficiency by HRT or other antiresorptive therapies and minimal suppressive dosages of LT4 are attempts to optimize the care of patients with DTC. In postmenopausal patients with DTC and patients with DTC who require LT4 dosages in excess of 2.6 μg/kg, the information provided by markers of bone metabolism may help to prevent bone damage.